4//SEC Filing
Leamon Christopher P 4
Accession 0000950170-24-002301
CIK 0001805890other
Filed
Jan 4, 7:00 PM ET
Accepted
Jan 5, 8:54 AM ET
Size
9.2 KB
Accession
0000950170-24-002301
Insider Transaction Report
Form 4
Leamon Christopher P
Chief Scientific Officer
Transactions
- Award
Common Stock
2023-08-31+11,957→ 11,957 total - Award
Stock Option (Right to Buy)
2024-01-04+106,100→ 106,100 totalExercise: $8.44Exp: 2034-01-04→ Common Stock (106,100 underlying) - Award
Restricted Stock Units
2024-01-04+63,700→ 63,700 total→ Common Stock (63,700 underlying)
Footnotes (4)
- [F1]These shares were purchased pursuant to the Issuer's 2020 Employee Stock Purchase Plan.
- [F2]This option vests in 48 equal monthly installments beginning on February 4, 2024.
- [F3]Each restricted stock unit represents a contingent right to receive one share of common stock of Fusion Pharmaceuticals Inc. for no consideration.
- [F4]The restricted stock units vest in six equal installments on each of July 4, 2024, January 4, 2025, July 4, 2025, January 4, 2026, July 4, 2026 and January 4, 2027.
Documents
Issuer
Fusion Pharmaceuticals Inc.
CIK 0001805890
Entity typeother
Related Parties
1- filerCIK 0001509415
Filing Metadata
- Form type
- 4
- Filed
- Jan 4, 7:00 PM ET
- Accepted
- Jan 5, 8:54 AM ET
- Size
- 9.2 KB